Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.

Cross-talk between insulin-like growth factor (IGF)- and estrogen receptor (ER)-signaling pathways results in synergistic growth. We show here that estrogen enhances IGF signaling by inducing expression of three key IGF-regulatory molecules, the type 1 IGF receptor (IGFR1) and its downstream signaling molecules, insulin receptor substrate (IRS)-1 and IRS-2. Estrogen induction of IGFR1 and IRS expression resulted in enhanced tyrosine phosphorylation of IRS-1 after IGF-I stimulation, followed by enhanced mitogen-activated protein kinase activation. To examine whether these pathways were similarly activated in vivo, we examined MCF-7 cells grown as xenografts in athymic mice. IRS-1 was expressed at high levels in estrogen-dependent growth of MCF-7 xenografts, but withdrawal of estrogen, which decreased tumor growth, resulted in a dramatic decrease in IRS-1 expression. Finally, we have shown that high IRS-1 expression is an indicator of early disease recurrence in ER-positive human primary breast tumors. Taken together, these data not only reinforce the concept of cross-talk between IGF- and ER-signaling pathways, but indicate that IGF molecules may be critical regulators of estrogen-mediated growth and breast cancer pathogenesis.

[1]  D. Yee,et al.  Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells* , 1998, The Journal of Biological Chemistry.

[2]  G. Freiss,et al.  Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells. , 1998, Molecular endocrinology.

[3]  M. Prisco,et al.  Differential roles of IRS‐1 and SHC signaling pathways in breast cancer cells , 1997, International journal of cancer.

[4]  E. Surmacz,et al.  Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. , 1997, Cancer research.

[5]  R. Weinberg,et al.  Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution , 1997, Molecular and cellular biology.

[6]  S. Hilsenbeck,et al.  Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. , 1997, European journal of cancer.

[7]  M. White,et al.  The IRS‐signalling system during insulin and cytokine action , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.

[8]  R. Sutherland,et al.  Estrogen-induced Activation of Cdk4 and Cdk2 during G1-S Phase Progression Is Accompanied by Increased Cyclin D1 Expression and Decreased Cyclin-dependent Kinase Inhibitor Association with Cyclin E-Cdk2* , 1997, The Journal of Biological Chemistry.

[9]  S. Hilsenbeck,et al.  Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  D. Yee,et al.  Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. , 1997, The Journal of endocrinology.

[11]  H. Huynh,et al.  Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  P. Petrusz,et al.  Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  L. Altucci,et al.  17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. , 1996, Oncogene.

[14]  A. Maggi,et al.  Cross-coupling between insulin and estrogen receptor in human neuroblastoma cells. , 1996, Molecular endocrinology.

[15]  F. May,et al.  Paradoxical effects of overexpression of the type I insulin-like growth factor (IGF) receptor on the responsiveness of human breast cancer cells to IGFs and estradiol. , 1996, Endocrinology.

[16]  H. Huynh,et al.  Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. , 1996, Cancer research.

[17]  M. Pollak,et al.  Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells (*) , 1996, The Journal of Biological Chemistry.

[18]  D. Leroith.  Insulin-like growth factor receptors and binding proteins. , 1996, Bailliere's clinical endocrinology and metabolism.

[19]  E. Surmacz,et al.  Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  C. Kahn,et al.  Characterization and regulation of the mouse insulin receptor substrate gene promoter. , 1995, Molecular endocrinology.

[21]  R. Baserga,et al.  Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[22]  M. Phillip,et al.  Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol. , 1995, Endocrinology.

[23]  S. Hilsenbeck,et al.  Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. , 1995, Journal of the National Cancer Institute.

[24]  G. Lienhard,et al.  Transforming potential of the insulin receptor substrate 1. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[25]  R. Wieczorek,et al.  Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. , 1995, Endocrinology.

[26]  S. Hilsenbeck,et al.  Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. , 1994, Journal of the National Cancer Institute.

[27]  L. M. Facchini,et al.  Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. , 1994, Oncogene.

[28]  G. Freiss,et al.  Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. , 1994, Molecular endocrinology.

[29]  Y. Yamasaki,et al.  Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. , 1994, The Journal of biological chemistry.

[30]  S. Safe,et al.  Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. , 1994, The Journal of biological chemistry.

[31]  U. Pagotto,et al.  The unliganded estrogen receptor (ER) transduces growth factor signals , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  O. Jänne,et al.  [Nuclear hormone receptors]. , 1994, Duodecim; laaketieteellinen aikakauskirja.

[33]  A. Philips,et al.  Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. , 1993, The Journal of biological chemistry.

[34]  D. Yee,et al.  Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action. , 1992, Journal of the National Cancer Institute.

[35]  R. Shiu,et al.  Mechanism of estrogen activation of c-myc oncogene expression. , 1992, Oncogene.

[36]  P. Chambon,et al.  A far upstream estrogen response element of the ovalbumin gene contains several half-palindromic 5′-TGACC-3′ motifs acting synergistically , 1992, Cell.

[37]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[38]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[39]  K J Cullen,et al.  Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression. , 1992, Molecular endocrinology.

[40]  R. Daly,et al.  Autocrine production of insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[41]  J. Laborda,et al.  36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. , 1991, Nucleic acids research.

[42]  H. Rochefort,et al.  Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: a receptor saturation mechanism to increase the secretion of lysosomal proenzymes. , 1991, Molecular endocrinology.

[43]  M. Johnson,et al.  Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. , 1990, The Journal of biological chemistry.

[44]  B. Katzenellenbogen,et al.  Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. , 1990, Endocrinology.

[45]  D. Yee,et al.  Identification of an alternate type I insulin-like growth factor receptor beta subunit mRNA transcript. , 1989, The Journal of biological chemistry.

[46]  C. Osborne,et al.  Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. , 1989, Molecular endocrinology.

[47]  C. Osborne,et al.  Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. , 1989, The Journal of clinical investigation.

[48]  D. Yee,et al.  Insulin-like growth factor II mRNA expression in human breast cancer. , 1988, Cancer research.

[49]  E. Gelmann,et al.  Growth regulation of human breast carcinoma occurs through regulated growth factor secretion , 1987, Journal of cellular biochemistry.

[50]  R. Dickson,et al.  Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. , 1987, Endocrine reviews.

[51]  M. Sporn,et al.  Autocrine secretion and malignant transformation of cells. , 1980, The New England journal of medicine.

[52]  A. Pardee,et al.  A restriction point for control of normal animal cell proliferation. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[53]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .